Clinical Trials

NCT IdNCT04108013
TitleA Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
ConditionLung Cancer Stage II
StudyTypeInterventional
OrganizationXuanwu Hospital, Beijing
Sponsor/CollaboratorsXuanwu Hospital, Beijing
StatusNot yet recruiting
GenderAll
AgeGroupAdult
Older Adult
Location (with distance)
DescriptionThis study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.